Avadel Pharmaceuticals plc

NASDAQ (USD): Avadel Pharmaceuticals plc (AVDL)

Last Price

7.72

Today's Change

-2.965 (27.73%)

Day's Change

7.39 - 8.23

Trading Volume

5,940,392

Overview

Market Cap

744 Million

Shares Outstanding

96 Million

Avg Volume

1,246,916

Avg Price (50 Days)

11.64

Avg Price (200 Days)

14.50

PE Ratio

-10.30

EPS

-0.75

Earnings Announcement

03-Mar-2025

Previous Close

10.69

Open

8.06

Day's Range

7.39 - 8.23

Year Range

7.39 - 19.09

Trading Volume

5,940,803

Price Change Highlight

1 Day Change

-27.74%

5 Day Change

-30.22%

1 Month Change

-22.75%

3 Month Change

-40.39%

6 Month Change

-52.08%

Ytd Change

-29.77%

1 Year Change

-48.47%

3 Year Change

11.63%

5 Year Change

11.96%

10 Year Change

-57.62%

Max Change

-34.26%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—Specialty & Generic

Description:

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment